Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology

医学 丙酸氟替卡松 哮喘 维持疗法 氟替卡松 皮质类固醇 治疗指标 不利影响 术语 维持剂量 重症监护医学 内科学 药理学 药品 化疗 哲学 语言学
作者
Richard W. Beasley,James Harper,Grace E. Bird,Ingrid Maijers,Mark Weatherall,Ian Douglas Pavord
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:199 (12): 1471-1477 被引量:164
标识
DOI:10.1164/rccm.201810-1868ci
摘要

The Global Initiative for Asthma guidelines use the traditional terminology of "low," "medium," and "high" doses of inhaled corticosteroids (ICS) to define daily maintenance doses of 100 to 250 μg, >250 to 500 μg, and >500 μg, respectively, of fluticasone propionate or equivalent for adults with asthma. This concise clinical review proposes that this terminology is not evidence based and that prescribing practice based on this terminology may lead to the use of inappropriately excessive doses of ICS. Specifically, the ICS dose that achieves 80-90% of the maximum obtainable benefit is currently classified as a low dose, with the description of two higher dose levels of medium and high, which are associated with significant risk of systemic adverse effects. Asthma guidelines and clinician prescribing practice need to be modified in accordance with the currently available evidence of the dose-response relationship of ICS in adult asthma. We propose a reclassification of ICS doses based on a "standard daily dose," which is defined as 200-250 μg of fluticasone propionate or equivalent, representing the dose at which approximately 80-90% of the maximum achievable therapeutic benefit of ICS is obtained in adult asthma across the spectrum of severity. It is recommended that ICS treatment be started at these standard doses, which then represent the doses at which maintenance ICS are prescribed at step 2 and within ICS/long-acting β-agonist combination therapy at step 3. The opportunity is available to prescribe higher doses within ICS/long-acting β-agonist maintenance therapy in accordance with the stepwise approach to asthma treatment at step 4.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wangwangwang完成签到,获得积分10
刚刚
刚刚
Akim的应助被01采纳,获得10
1秒前
1秒前
白雪公主完成签到,获得积分20
3秒前
3秒前
一切都好完成签到,获得积分20
3秒前
4秒前
4秒前
115完成签到,获得积分10
5秒前
小杨想毕业完成签到,获得积分10
5秒前
Adonfth发布了新的文献求助10
5秒前
dew发布了新的文献求助10
5秒前
外向的烟发布了新的文献求助10
5秒前
蓝天的应助被宗友绿采纳,获得10
6秒前
可可萝oxo发布了新的文献求助10
6秒前
htt发布了新的文献求助10
7秒前
7秒前
麤七发布了新的文献求助100
8秒前
aging发布了新的文献求助10
10秒前
10秒前
白雪公主关注了科研通微信公众号
10秒前
嘿嘿发布了新的文献求助10
10秒前
wyx完成签到,获得积分10
11秒前
12秒前
anna1992发布了新的文献求助10
13秒前
waiting完成签到,获得积分10
13秒前
13秒前
洁洁完成签到,获得积分10
14秒前
小郭子的应助被小可爱采纳,获得10
14秒前
Owen的应助被夏花苍葬采纳,获得10
14秒前
可爱的函函的应助被wei采纳,获得10
16秒前
老实诗柳完成签到,获得积分10
17秒前
张星星发布了新的文献求助10
18秒前
求求各位大哥救救小弟我吧完成签到,获得积分10
18秒前
18秒前
18秒前
森离九完成签到,获得积分10
18秒前
许艺议完成签到 ,获得积分10
18秒前
海辰完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163614
求助须知:如何正确求助?哪些是违规求助? 9557702
关于积分的说明 21741573
捐赠科研通 7754282
什么是DOI,文献DOI怎么找? 3428275
关于科研通互助平台的介绍 2552989
邀请新用户注册赠送积分活动 2472923